If you are currently on the lookout for pharmaceutical stocks, then it could be a good time to consider taking a closer look into the Relief Therapeutics Holding AG (OTCQB:RLFTF) stock. The company was in the news this past Friday after it came up with a key update with regards to a potential reverse merger.
The Update
The reverse merger that the company had been contemplating had been with Renexxion Inc., a United States-based, privately held, clinical-stage biotech firm with a special focus on therapies for gastrointestinal disorders. The company announced that after the signing of the non-binding letter of intent earlier in 2024, the two entities had made significant progress in the advancement of their potentially transformational partnership.
Further Information
The two companies were engaged in close consultation to make sure that the transaction proved to be a success in the long term. The current efforts were largely focused on the structuring of the deal and integration planning so as to support the future growth of the eventual merged entity. Relief Therapeutics Holding stated that it expected that the merger agreement will be formally closed in the first fiscal quarter of 2025. It may be a good time to keep an eye on the stock today.
Management Quote
“As we continue discussions with Renexxion, we are focused on leveraging the complementary strengths of both companies to maximize value for our shareholders and stakeholders,” commented Dr. Raghuram Selvaraju, chairman of the board of directors of Relief. “At the same time, we are building on the recent advancements in Relief’s core development programs, with critical milestones expected in the coming year.”
Fundamentals
| P/E Ratio | -1.09 |
| PEG Ratio | 1.2 |
| Price to Book | 1.04 |
| Price to Cash Flow | – |
| Price to Free Cash Flow | – |
| Total Sales (TTM) | 9.67 M |
| Revenue per Share (TTM) | 0.77 |
| Shares Outstanding | 12.540 M |
| Share Float (%) | 8.26 M (65.83%) |
| % Held by Institutions | 5.77 |
